Our Research Concerns:

  • why adoptive cell therapies, the type of immunotherapy in which tumor-specific T cells (e.g. CAR-T cells) are given to a patient to help the body fight cancer, aren’t effective against solid tumors like they are against leukemias and lymphomas.
  • Overcoming resistance of CAR-T cell therapy in multiple myeloma.
  • The new tumor-specific Th9 cell-paradigm to eradicate advanced human tumors.

Since 2020, Dr. Lu has been awarded, as the PI, 4 R01s from NCI, 1 ACS research scholar grant, 3 cancer foundation grants, and numerous intramural and industry grants. In addition to the CPRIT Rising Star award, Dr. Lu was the winner of New Drug Development Global Campaign in 2019 held by Daiichi Sankyo Co., Ltd.

Recent representative corresponding-authored publications include: Briefings in Bioinformatics 2022 (PMID: 35037026), Cancer Cell 2022 (PMID: 34678150); Nature Biomedical Engineering 2021 (PMID: 34725506); Nature Comm 2019 (PMID: 30914642); Cancer Cell 2018 (PMID: 29894691); Nature Comm 2016 (PMID: 27492902)